The hippo signaling pathway in pancreatic cancer

Research output: Contribution to journalReview article


Hippo signaling is a key regulator of organ size, tissue hemostasis and regeneration. Dysregulation of the Hippo pathway has been recognized in a variety of human cancers, including pancreatic cancer. YES-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are the two major downstream effectors of the Hippo pathway. YAP and TAZ have been found to promote pancreatic tumor development and progression, even in the absence of mutant Kirsten RAS (KRAS). Pancreatic cancer is associated with an abundant stromal reaction leading to tumor growth and immune escape. It has been found that YAP and TAZ modulate behavior of pancreatic stellate cells and recruitment of tumor-associated macrophages and myeloid-derived suppressor cells. Moreover, YAP and TAZ are associated with chemoresistance and poor prognosis in pancreatic cancer. This review dissects the role of Hippo signaling in pancreatic cancer, focusing on molecular mechanisms and prospects for future intervention.


External organisations
  • Skåne University Hospital
  • Wenzhou Medical University
  • Lund University
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
  • Cell Biology


  • Chemoresistance, EMT, Hippo pathway, Immunomodulation, Pancreatic Cancer, Review, Stroma, TAZ, Treatment, Tumor progression, YAP
Original languageEnglish
Pages (from-to)3317-3321
Number of pages5
JournalAnticancer research
Issue number7
Publication statusPublished - 2019 Jul
Publication categoryResearch